101
|
Govindarajan A, Naimark D, Coburn NG, Smith AJ, Law CHL. Use of colonic stents in emergent malignant left colonic obstruction: a Markov chain Monte Carlo decision analysis. Dis Colon Rectum 2007; 50:1811-24. [PMID: 17899279 DOI: 10.1007/s10350-007-9047-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2006] [Revised: 04/11/2007] [Accepted: 05/26/2007] [Indexed: 02/08/2023]
Abstract
PURPOSE This decision analysis examines the cost-effectiveness of colonic stenting as a bridge to surgery vs. surgery alone in the management of emergent, malignant left colonic obstruction. METHODS We used a Markov chain Monte Carlo decision analysis model to determine the effect on health-related quality of life of two strategies: emergency surgery vs. emergency colonic stenting as a bridge to definitive surgery. All relevant health states were modeled during a patient's expected lifespan. Outcome measures were mortality, the proportion of patients requiring a colostomy, quality-adjusted life expectancy, and costs. Deterministic and probabilistic sensitivity analyses were performed. RESULTS In our model, colonic stenting was more effective (9.2 quality-adjusted life months benefit) and less costly (CAD dollars 3,763; US dollars 3,135) than emergency surgery. Its benefits were secondary to reductions in acute mortality and in the likelihood of requiring a permanent colostomy. The results were only dependent on the rate of stenting complications (perforation, technical placement failure, and migration) and the patient's risk of surgical mortality, with the benefits being greatest among patients at high risk of operative mortality. CONCLUSIONS Colonic stenting as a bridge to surgery is more effective and less costly than surgery in the treatment of emergent, malignant left colonic obstruction. The benefits are most pronounced in high-risk patients and are diminished by increases in stent placement failure rates and perforation rates. In low-risk patients, the benefits are more modest and may not outweigh the risks.
Collapse
|
102
|
Manari A, Costa E, Scivales A, Ponzi P, Di Stasi F, Guiducci V, Pignatelli G, Giacometti P. Economic appraisal of the angioplasty procedures performed in 2004 in a high-volume diagnostic and interventional cardiology unit. J Cardiovasc Med (Hagerstown) 2007; 8:792-8. [PMID: 17885516 DOI: 10.2459/jcm.0b013e328012c1b6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE Growing interest in the use of drug-eluting stents (DESs) in coronary angioplasty has prompted the Healthcare Agency of the Emilia Romagna Region to draw up recommendations for their appropriate clinical use in high-risk patients. Since the adoption of any new technology necessitates economic appraisal, we analysed the resource consumption of the various types of angioplasty procedures and the impact on the budget of a cardiology department. METHODS A retrospective economic appraisal was carried out on the coronary angioplasty procedures performed in 2004 in the Department of Interventional Cardiology of Reggio Emilia. On the basis of the principles of activity-based costing, detailed hospital costs were estimated for each procedure and compared with the relevant diagnosis-related group (DRG) reimbursement. RESULTS In 2004, the Reggio Emilia hospital performed 806 angioplasty procedures for a total expenditure of euro 5,176,268. These were 93 plain old balloon angioplasty procedures (euro 487,329), 401 procedures with bare-metal stents (euro 2,380,071), 249 procedures with DESs (euro 1,827,386) and 63 mixed procedures (euro 481,480). Reimbursements amounted to euro 5,816,748 (11% from plain old balloon angioplasty, 50% from bare-metal stent, 31% from DES and 8% from mixed procedures) with a positive margin of about euro 680,480 between costs incurred and reimbursements obtained, even if the reimbursement for DES and mixed procedures was not covering all the incurred costs. CONCLUSIONS Analysis of the case-mix of procedures revealed that an overall positive margin between costs and DRG reimbursements was achieved. It therefore emerges that adherence to the indications of the Healthcare Agency of the Emilia Romagna Region for the appropriate clinical use of DESs is economically sustainable from the hospital enterprise point of view, although the DRG reimbursements are not able to differentiate among resource consumptions owing to the adoption of innovative technologies.
Collapse
|
103
|
Varani E, Balducelli M, Vecchi G, Aquilina M, Maresta A. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease. J Cardiovasc Med (Hagerstown) 2007; 8:596-601. [PMID: 17667030 DOI: 10.2459/jcm.0b013e32801051f4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVES One hundred and eleven consecutive patients with multivessel coronary artery disease treated with percutaneous coronary intervention with multiple drug-eluting stents were examined to investigate 1-year clinical results and initial and total costs. METHODS Clinical and procedural characteristics, duration of hospital stay and 12-month follow-up events were considered. Real costs of multivessel percutaneous coronary intervention with multiple drug-eluting stents were calculated, including disposables, personnel, equipment depreciation and hospital stay, whereas medical resources consumption at 12 months were calculated as disease related group reimbursement tariffs. RESULTS The patient population (69% males, mean age 65 +/- 10 years) presented mid to high-risk clinical and anatomical characteristics. The mean number of treated vessels was 2.36 per patient with 2.8 drug-eluting stents per patient. A complete revascularization was achieved in 70% of cases. In-hospital events were post-procedural non-Q myocardial infarction in 5.4% and two retroperitoneal haemorrhages. Post-procedural hospital stay was 2.5 +/- 2.3 days (mean total hospital stay = 5.3 +/- 3 days). At 12-month follow-up, total mortality and acute myocardial infarction incidence were 3.6% and 1.8%, respectively; only one patient (0.9%) presented subacute stent thrombosis at 3 months, which was treated by urgent re-percutaneous coronary intervention. Target vessel revascularization rate was 12.6% and the incidence of cumulative major adverse cardiac events was 15.3%. Initial hospital costs were 8992 euros +/- 2825 (5518 euros +/- 1098 for procedure and 3473 euros+/- 2347 for hospital stay); follow-up costs were 222 euros+/- 3087, leading to 12-month total costs of 10214 euros+/- 4184. CONCLUSIONS Multivessel percutaneous coronary intervention with drug-eluting stents showed good early and medium-term results with acceptable total costs. Despite not completely being covered by actual disease related group reimbursement, the initial and final costs were substantially lower than that of disease related group reimbursement for coronary artery bypass graft.
Collapse
|
104
|
Abstract
The introduction of percutaneous transluminal coronary angioplasty (PTCA) revolutionized the surgical treatment of coronary artery disease. However, despite increased surgical experience and technical breakthroughs, restenosis occurs in 30%-50% of patients undergoing simple balloon angioplasty and in 10%-30% of patients who receive an intravascular stent. Animal and human data indicate that restenosis is a response to injury incurred during PTCA. The need for reintervention in a high percentage of patients due to restenosis remains an important limitation to the long-term success of PTCA. Stenting reduces initial elastic recoil and limits negative arterial remodeling; however, bare-metal stents may promote intimal hyperplasia by eliciting an immune and proliferative response. Consistent with these data, clinical studies suggest that drug-eluting stents, coated with anti-inflammatory or antiproliferative agents, reduce the risk for restenosis. Stenting represents a considerable cost burden. Treatment strategy should focus on selective use of expensive drug-eluting stents in populations where they have been found to be more clinically effective than bare-metal stents--patients who are at high risk for restenosis or who develop restenosis with bare-metal stents. Recent studies suggest that the pharmacologic management of restenosis is now feasible. Together, the judicious use of stents and oral pharmacotherapy promise to reduce the risk for restenosis, even among high-risk patients.
Collapse
|
105
|
Pawaskar M, Satiani B, Balkrishnan R, Starr JE. Economic Evaluation of Carotid Artery Stenting Versus Carotid Endarterectomy for the Treatment of Carotid Artery Stenosis. J Am Coll Surg 2007; 205:413-9. [PMID: 17765157 DOI: 10.1016/j.jamcollsurg.2007.04.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2007] [Revised: 04/09/2007] [Accepted: 04/09/2007] [Indexed: 10/23/2022]
Abstract
BACKGROUND The clinical effectiveness of carotid endarterectomy (CEA) is well established. But the economic impact of CEA and carotid artery stenting (CAS) is still uncertain. The objective of this study was to compare hospital costs and reimbursement for CAS and CEA. STUDY DESIGN We performed a retrospective database analysis on pair-matched patients who underwent CEA (n = 31) and CAS (n = 31) at the Richard M Ross Heart Hospital in Columbus, OH. The hospital's clinical and financial databases were used to obtain patient-specific information and procedural charges. Cost data were generated by applying the hospital's ratio of cost to charges for all DRG charges. The Wilcoxon signed-rank test was used to examine the differences between costs of these procedures. RESULTS Data are reported as mean +/- SD. The mean age of patients in CAS group was 70.14 years (+/- 1.60 years) versus 68.64 years (+/- 1.75 years) for CEA patients (p < 0.05). The total direct cost associated with CEA ($3,765.12+/-$2,170.82) was significantly lower than the CAS cost ($8,219.71+/-$2,958.55, p < 0.001). The mean procedural cost for CAS ($7,543.61+/-$2,886.54) was significantly higher than that for CEA ($2,720.00+/-$926.38, p < 0.001). The hospital experienced cost savings of $9,690.87 for CEA versus $4,804.79 for CAS from private insurance. Similarly, savings obtained by Medicare-enrolled CEA patients were higher than those for CAS patients ($1,497.79). CONCLUSIONS CAS is significantly more expensive than CEA, with a major portion of cost attributed to the total procedural cost. The hospital experienced significant savings from CEA procedures compared with CAS under all DRG classifications and insurers. Hospitals must develop new financial strategies and improve the efficiency of infrastructure to make CAS financially viable.
Collapse
|
106
|
Nguyen LL. Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation. J Vasc Surg 2007; 45 Suppl A:A149-57. [PMID: 17544036 PMCID: PMC2909598 DOI: 10.1016/j.jvs.2007.02.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2006] [Accepted: 02/11/2007] [Indexed: 10/23/2022]
Abstract
Peripheral arterial disease (PAD) is a growing health problem for many Americans and often occurs along with other cardiovascular risk factors, including diabetes mellitus (DM), low-grade inflammation, hypertension, and lipid disorders. Intermittent claudication (IC), an early manifestation of PAD, commonly leads to reduced quality of life for patients who are limited in their ambulation. While recent wide adoption of percutaneous peripheral interventional (PPI) techniques has increased the number patients being aggressively treated for IC, the overall effectiveness of PPI for the treatment of IC is not well known, especially for DM patients who have both hemodynamic and functional obstacles to treatment success. This review is designed to illustrate how treatment outcomes for IC can be measured by different modalities and how diabetes and inflammation can influence those outcomes. In the setting of greater concern for health care resources and clinical accountability, better understanding of treatment outcomes and efficacy will help us manage these complex challenges.
Collapse
|
107
|
Yasunaga H, Ide H, Imamura T, Ohe K. Price disparity of percutaneous coronary intervention devices in Japan and the United States in 2006. Circ J 2007; 71:1128-30. [PMID: 17587722 DOI: 10.1253/circj.71.1128] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND The price disparity between Japan and foreign countries for medical devices is a controversial issue. Price differences existed between Japan and USA for various medical devices in early 2005, so in the present study, a more precise and detailed investigation of the latest market prices of medical devices between Japan and USA was conducted in 2006, focusing on coronary stents and percutaneous transluminal coronary angioplasty (PTCA) catheters, for an evaluation of the efficacy of current Japanese policies. METHODS AND RESULTS Japanese market prices were obtained from 31 university hospitals, and US market prices were obtained from 1 hospital chain and 2 group-purchasing organizations. The price ratio (Japanese market price/US market price) was determined to be 1.2-1.4 for drug-eluting stents (DES), 1.6-2.4 for non-DES, and 4.1-5.1 for PTCA catheters. CONCLUSIONS Results showed that the price disparity was relatively small for DES, but still significant for non-DES and PTCA catheters. Radical measures must be taken to improve the fundamental causes of price disparity and might include reviewing the implementation of the Japanese Pharmaceutical Affairs Law, abolishing the reimbursement price system for medical devices, and establishing centers of clinical excellence.
Collapse
|
108
|
Odell A, Landelius P, Astrom-Olsson K, Grip L. The impact of general usage of stents on short- and long-term health care costs following percutaneous coronary intervention. Cardiology 2007; 109:85-92. [PMID: 17664872 DOI: 10.1159/000105547] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2006] [Accepted: 11/16/2006] [Indexed: 11/19/2022]
Abstract
BACKGROUND The general usage of stents during percutaneous coronary intervention (PCI) reduces the need for subsequent repeated revascularizations when compared with balloon dilatation. The aim was to evaluate the impact of stenting on short- and long-term in-hospital care costs after PCI. METHOD AND RESULTS Patients who underwent PCI from July 1992 to June 1993 (group A, n = 166; 4.2% stents) and from July 1996 to June 1997 (group B, n = 233; 61.4% stents) were included. The clinical outcome and all in-hospital care costs during 2.5 years following the procedures were analyzed. During the study period the number of deaths and acute myocardial infarctions was similar in the groups, but repeated revascularization occurred more often in group A than in group B (53.6 vs. 39.5%; p = 0.007). The initial procedural cost per patient was higher in group B than in group A (EUR 7,653 +/- 5,071 vs. EUR 6,048 +/- 3,242; p = 0.002), but after 2.5 years the costs were similar in the 2 groups (not significant). CONCLUSION General usage of stents increases immediate health care cost compared with balloon dilatation, but despite reduction in subsequent revascularization, there is no reduction in long-term in-hospital costs.
Collapse
|
109
|
Kakafika AI, Mikhailidis DP, Wierzbicki AS, Karagiannis A, Athyros VG. PCI and stable coronary heart disease--COURAGE to change our minds? Curr Vasc Pharmacol 2007; 5:173-4. [PMID: 17627560 DOI: 10.2174/157016107781024145] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
110
|
Westaby S, Channon K, Banning A. To stent or not to stent?: A sterile debate. BMJ 2007; 335:111. [PMID: 17641307 PMCID: PMC1925204 DOI: 10.1136/bmj.39273.655694.be] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
111
|
Agostoni P, Vermeersch P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28:1912-3; author reply 1913. [PMID: 17606468 DOI: 10.1093/eurheartj/ehm205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
112
|
Ansel GM. Ground hog day. Catheter Cardiovasc Interv 2007; 70:155. [PMID: 17585393 DOI: 10.1002/ccd.21275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
113
|
Bosco J. Covered self-expanding metal stents for postoperative bile leaks: is the expense worth the expanse? Gastrointest Endosc 2007; 66:60-1. [PMID: 17591474 DOI: 10.1016/j.gie.2007.02.038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2007] [Accepted: 02/17/2007] [Indexed: 12/10/2022]
|
114
|
Taggart D. Should your patient have CABG or stents? THE PRACTITIONER 2007; 251:59-60, 62, 64-5. [PMID: 17654876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
115
|
Remmel M, Hartmann F, Harland LC, Schunkert H, Radke PW. Rational use of drug-eluting stents: a comparison of different policies. Crit Pathw Cardiol 2007; 6:85-9. [PMID: 17667871 DOI: 10.1097/hpc.0b013e318053d16f] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Long-term results of recent landmark trials document both benefits and risks of drug-eluting stents (DES) for coronary revascularization. Interestingly, the conclusions drawn from these data vary widely since significant differences in DES penetration rates become obvious when the utilization of this technology is compared between hospitals or even countries. Based on the recommendations of the European Society of Cardiology, the FDA as well as data derived from the BASKET-LATE study, we propose that a maximum penetration rate of 50% for DES seems appropriate at present. Analysis of the length/diameter distribution combined with the use of validated restenosis reference charts allows identification of high-risk patients regarding restenosis risk and modeling the use of DES depending on financial resources and clinical indication. Such algorithm provides the rational for preprocedural risk stratification and efficient use of resources.
Collapse
|
116
|
Drug-eluting stent prices steady, usage declined over past several months. HOSPITAL MATERIAL[DOLLAR SIGN] MANAGEMENT 2007; 32:1, 5-8. [PMID: 17612009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
117
|
Falcone EL, Tangri N. Drug-eluting stents. CMAJ 2007; 176:1611. [PMID: 17515590 PMCID: PMC1867843 DOI: 10.1503/cmaj.1070022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
118
|
Rinfret S, Schampaert E. Drug-eluting stents. CMAJ 2007; 176:1611-2. [PMID: 17515589 PMCID: PMC1867850 DOI: 10.1503/cmaj.1070021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
119
|
Cohen DJ, Bakhai A. Drug-eluting stents. CMAJ 2007; 176:1612. [PMID: 17515592 PMCID: PMC1867834 DOI: 10.1503/cmaj.1070046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
120
|
Rhea S. CMS backtracks on stenting. Carotid artery procedure will not be covered. MODERN HEALTHCARE 2007; 37:8-9. [PMID: 17577916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
|
121
|
Zijlstra F. [Benefits and risks of drug-eluting stents]. NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE 2007; 151:1005-7. [PMID: 17508683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
The March 8, 2007-issue of the New England Journal of Medicine contained 5 original articles, 2 commentaries and 1 editorial on drug-eluting coronary stents versus bare metal stents. Over the past 5 years, multiple randomised, controlled trials have shown that drug-eluting stents reduce recurrent stenosis and the need for additional revascularisation procedures. Drug-eluting stents are now used in a large proportion of percutaneous coronary interventions. Following publications reporting a risk of late thrombosis with sudden occlusion, the promises and uncertainties regarding the benefits and risks are now heavily debated. It can be concluded that these first-generation drug-eluting stents, provided that they are used for indications in accordance with the randomised trials, result in a clear reduction in the need for additional revascularisation procedures without an effect on long-term case fatality and myocardial infarction. There is a small but serious risk of sudden thrombosis and occlusion. The task for the future will be to develop stents that do reduce recurrent stenosis but allow a normal endothelisation of the treated coronary artery segment. When drug-eluting stents have reached that stage, they will be clearly advantageous.
Collapse
|
122
|
Omeish AF. The cost of new therapies in cardiovascular care. Time for hope or despair for developing countries. Saudi Med J 2007; 28:675-82. [PMID: 17457431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023] Open
Abstract
In recent years, remarkable therapeutic advances have been made in the field of interventional cardiology with the introduction of statins, thienopyridines, such as clopidogrel and drug-eluting stents. Only a small minority in developing countries can afford these new treatment modalities, while the public health system would be rapidly bankrupted if it were to provide these modalities for all patients who might benefit from it. The purpose of this review article is to provide insight regarding the cost-effectiveness of these new treatment strategies and to address the added costs resulting upon their adoption and their appropriateness in developing countries.
Collapse
|
123
|
Kahaleh M, Brock A, Conaway MR, Shami VM, Dumonceau JM, Northup PG, Tokar J, Rich TA, Adams RB, Yeaton P. Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis. Endoscopy 2007; 39:319-24. [PMID: 17357951 DOI: 10.1055/s-2007-966263] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
BACKGROUND AND STUDY AIMS The current treatment model for the management of malignant biliary obstruction is to place a plastic stent for unstaged pancreatic cancer. In patients with unresectable disease but a life expectancy of more than 6 months, self-expandable metal stents (SEMS) are favored because of their more prolonged patency. We analyzed the efficacy and cost-effectiveness of covered SEMS (CSEMS) in patients with pancreatic cancer and distal biliary obstruction without regard to surgical resectability. PATIENTS AND METHODS Between March 2001 and March 2005, 101 consecutive patients with obstructive jaundice secondary to pancreatic cancer underwent placement of a CSEMS. Patients with resectable tumor were offered pancreaticoduodenectomy. A model was developed to compare the costs of CSEMS and polyethylene and DoubleLayer stents. RESULTS A total of 21 patients underwent staging laparoscopy, of whom 16 had a resection (76%). The 85 patients who did not have a resection had a mean survival of 5.9 months (range 1-25 months) and a mean CSEMS patency duration of 5.5 months (range 1-16 months). Life-table analysis demonstrated CSEMS patency rates of 97% at 3 months, 85% at 6 months, and 68% at 12 months. In a cost model that accounted for polyethylene and DoubleLayer stent malfunction and surgical resections, initial CSEMS placement (3177 euros per patient) was a less costly intervention than either DoubleLayer stent placement (3224 euros per patient) or polyethylene stent placement with revision (3570 euros per patient). CONCLUSIONS Covered SEMS are an effective treatment for distal biliary obstructions caused by pancreatic carcinoma. Their prolonged patency and removability makes them an attractive option for biliary decompression, regardless of resectability. The strategy of initial covered SEMS placement might be the most cost-effective strategy in these patients.
Collapse
|
124
|
Rao C, Aziz O, Panesar SS, Jones C, Morris S, Darzi A, Athanasiou T. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. BMJ 2007; 334:621. [PMID: 17337457 PMCID: PMC1831990 DOI: 10.1136/bmj.39112.480023.be] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To compare the cost effectiveness of percutaneous transluminal coronary artery stenting with minimally invasive internal thoracic artery bypass for isolated lesions of the left anterior descending artery. DESIGN Cost effectiveness analysis. DATA SOURCES Embase, Medline, Cochrane, Google Scholar, and Health Technology Assessment databases (1966-2005), and reference sources for utility values and economical variables. METHODS Decision analytical modelling and Markov simulation were used to model medium and long term costs, quality of life, and cost effectiveness after either intervention using data from referenced sources. Probabilistic sensitivity and alternative analyses were used to investigate the effect of uncertainty about the value of model variables and model structure. RESULTS Stenting was the dominant strategy in the first two years, being both more effective and less costly than bypass surgery. In the third year bypass surgery still remained more expensive but became marginally more effective. As the incremental cost effectiveness was 1,108,130.40 pounds sterling (1 682,146.00 euros; $2,179,194) per quality adjusted life year (QALY), the additional effectiveness could not be said to justify the additional cost at this stage. By five years, however, the incremental cost effectiveness ratio of 28,042.95 pounds sterling per QALY began to compare favourably with other interventions. At 10 years the additional effectiveness of 0.132 QALYs (range -0.166 to 0.430) probably justified the additional cost of 829.02 pounds sterling (range 205.56 pounds sterling to 1452.48 pounds sterling), with an incremental cost effectiveness of 6274.02 pounds sterling per QALY. Sensitivity and alternative analysis showed the results were sensitive to the time horizon and stent type. CONCLUSIONS Minimally invasive left internal thoracic artery bypass may be a more cost effective medium and long term alternative to percutaneous transluminal coronary artery stenting.
Collapse
|
125
|
Groeneveld PW, Suh JJ, Matta MA. The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review. J Interv Cardiol 2007; 20:1-9. [PMID: 17300390 DOI: 10.1111/j.1540-8183.2007.00214.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES While the efficacy of drug-eluting coronary stents (DES) has been demonstrated by several clinical trials, the impact of DES on health-care costs and recipient quality of life (QOL) is controversial. We performed a systematic review of the published literature on DES costs and the QOL effects of restenosis and target vessel revascularization (TVR). METHODS Among 536 potential articles initially identified by a broad search, 12 publications ultimately met inclusion criteria. Data were independently abstracted, evaluated for quality and relevance, and summarized by two reviewers. Excessive heterogeneity among these studies prevented formal meta-analysis, thus a narrative synthesis of the literature was performed. RESULTS In four economic studies, DES recipients had 1,600 dollars-3,200 dollars higher up-front costs than recipients of bare metal stents, but the differences in total costs after 1 year were less pronounced (200 dollars-1,200 dollars), and estimates of the average cost of an avoided revascularization ranged widely (1,800 dollars-36,900 dollars). All eight QOL studies indicated that restenosis was associated with lower QOL, but only two studies quantified this in terms of quality-adjusted life years (QALYs), with estimates ranging from 0.06 to 0.08. An additional study estimated that the median willingness to pay to prevent restenosis was 2,400 dollars-3,600 dollars. CONCLUSIONS There is a lack of convergence in the literature on the cost of DES in avoiding TVR. There is more agreement that the average QALY benefit of an avoided revascularization is 0.04-0.08. This implies that use of DES in patients where the average cost per avoided revascularization exceeds 8,000 dollars may be less likely to be cost-effective.
Collapse
|